After tweaking the formula behind an mRNA flu vaccine, Moderna has finally met all the goals needed for a successful shot in a phase 3 trial. Now, CEO Stéphane Bancel is eyeing a launch as early as ...

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...

Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress In contemporary phase I trials, which often include drugs developed with a deep understanding of biology and with the use of ...